In vitro and vivo, the data confirmed that BRAFi, MEKi or BRAFi + MEKi administration alone could conspicuously elevate the protein level of pSTAT3 (705), activate STAT3 signaling, suppressing tumor apoptosis. The gene discussed is STAT3; the disease is neoplasm.